2020-2027 Analysis and Review Doxylamine Market

Doxylamine Market

Doxylamine Market By Clinical Application (Sleep Aid, Allergy and Nausea and Vomiting in Pregnancy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

16-04-2020 REP-HC-5066 40 Tables 112 pages Format

The doxylamine market was valued at USD679.6Mn by 2019. The rising prevalence of short term insomnia is the adult population throughout the globe primarily drives the doxylamine market growth. A constant rise in the allergic infections of the respiratory tract and nausea and vomiting encountered by women population during pregnancies further bolster the doxylamine market growth.

 Doxylamine Market

Doxylamine is a histamine H1 antagonist having sedative properties, it is chiefly used as an over the counter sedative agent as well as a prescribed hypnotic agent. It is also used in drug combinations for the treatment of allergic rhinitis and nausea and vomiting associated with pregnancy. Doxylamine is associated with drug-related adverse events such as dry mouth, headache, constipation, dizziness, etc. 

The major segments related to the doxylamine market are:

By Clinical Application (2017–2027; US$ Mn)

Sleep Aid


Nausea and Vomiting in Pregnancy (NVP)

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy


Geography Segment(2017–2027; US$ Mn)

North America

United States


United Kingdom
Rest of Europe

Asia Pacific

Rest of Asia Pacific

Latin America (LATAM)

Rest of Latin America

Middle East and Africa (MEA)

Rest of MEA

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global doxylamine market
  • The overall segmentation of the doxylamine market, by clinical application, distribution channel, and geography is minutely studied. Sleep aid and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • The constant rise in the number of patients suffering from short term insomnia worldwide
  • Promising results exhibited by doxylamine in combination with pyridoxine hydrochloride in the treatment of NVP

Report gist?

  • The study of the global doxylamine market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of doxylamine either alone or in combination for the treatment of insomnia, and respiratory allergic infection
  • The report will benefit researchers engaged in the combination drug formulation of doxylamine in the treatment of hyperemesis gravidarum
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to doxylamine market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Sleep aid is currently representing the largest market share in the clinical application segment for doxylamine market. As per the latest research citings presented by the World Health Organization (WHO), 83% of the people suffering from depression suffer from short term insomnia worldwide. Insomnia is considered one of the major risk factors associated with deaths caused due to motor vehicle accidents. The recommended dose of doxylamine succinate tablets is 25mg orally every evening 30 minutes before bedtime. According to the statistics provided by the American Academy of Allergy, Asthma & Immunology (AAAAI), approximately 10%-30% of the global population is suffering from allergic rhinitis. Doxylamine is used in combination with dextromethorphan hydrobromide or phenylephrine hydrochloride to treat allergic infections of the respiratory tract. Nausea and vomiting in pregnancy are anticipated to register impressive market growth in the near future on account of proactive family planning in the developed countries and approximately 50% of women encounter nausea and vomiting during pregnancies.

Hospital pharmacy is leading the distribution channel segment for the Doxylamine market. Doxylamine is a first-generation antihistaminic agent associated with severe side effects such as drowsiness, dry mouth constipation, etc. Hospital pharmacist ensures precise dispensing of the doxylamine drug posology in accordance with a doctor’s prescription. Retail pharmacy is gaining positive growth traction in the developing countries owing to the presence of flourishing generic drugs market and availability of doxylamine with different drug combination as an over the counter product.

North America is presently dominating the geography segment for the doxylamine market. As per the latest research citings presented by the National Institute of Health (NIH), approximately 1 in 4 American citizen develops insomnia each year. Constant rise in respiratory allergic infections further accentuates the doxylamine market growth. Affordable reimbursement scenario for the different formulations of doxylamine bolsters the market growth in the region. Europe is placed in the 2nd position in the regional segment for the doxylamine market. A significant increase in the reported cases of hyperemesis gravidarum in pregnant women in the European Union region primarily drives the doxylamine market growth in the region. The supportive regulatory environment provided by the European Medical Agency (EMA) for the sale and distribution of doxylamine strengthens the market growth in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period. Rising prevalence of insomnia in the adult population and availability of doxylamine as an OTC product drives the market growth in the Asia Pacific region.

Select License Type


Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.